These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26372402)

  • 1. Concentration-dependent effects of alendronate and pamidronate functionalized gold nanoparticles on osteoclast and osteoblast viability.
    Conners CM; Bhethanabotla VR; Gupta VK
    J Biomed Mater Res B Appl Biomater; 2017 Jan; 105(1):21-29. PubMed ID: 26372402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate-modified gold nanoparticles: a useful vehicle to study the treatment of osteonecrosis of the femoral head.
    Fanord F; Fairbairn K; Kim H; Garces A; Bhethanabotla V; Gupta VK
    Nanotechnology; 2011 Jan; 22(3):035102. PubMed ID: 21149961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
    Hussein O; Tiedemann K; Komarova SV
    Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.
    Hayden RS; Vollrath M; Kaplan DL
    Acta Biomater; 2014 Jan; 10(1):486-93. PubMed ID: 24096150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
    Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
    J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.
    Ohe JY; Kwon YD; Lee HW
    Clin Oral Investig; 2012 Aug; 16(4):1153-9. PubMed ID: 21938481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells.
    Panzavolta S; Torricelli P; Bracci B; Fini M; Bigi A
    J Inorg Biochem; 2009 Jan; 103(1):101-6. PubMed ID: 18977031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
    Schindeler A; Little DG
    Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin and alendronate multi-functionalized materials as tools to hinder oxidative stress damage.
    Forte L; Torricelli P; Boanini E; Rubini K; Fini M; Bigi A
    J Biomed Mater Res A; 2017 Dec; 105(12):3293-3303. PubMed ID: 28865182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
    Kim YH; Kim GS; Jeong-Hwa B
    Exp Mol Med; 2002 May; 34(2):145-51. PubMed ID: 12085990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.
    Wang Y; Panasiuk A; Grainger DW
    Mol Pharm; 2011 Aug; 8(4):1016-24. PubMed ID: 21186792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
    Frith JC; Rogers MJ
    J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
    Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
    Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium.
    Twiss IM; Pas O; Ramp-Koopmanschap W; Den Hartigh J; Vermeij P
    J Bone Miner Res; 1999 May; 14(5):784-91. PubMed ID: 10320527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting a therapeutically relevant concentration of alendronate for in vitro studies on osteoblasts.
    Krüger TB; Syversen U; Herlofson BB; Lian AM; Reseland JE
    Acta Odontol Scand; 2022 Nov; 80(8):619-625. PubMed ID: 35605138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of two novel bisphosphonates on bone cells in vitro.
    Evans CE; Braidman IP
    Bone Miner; 1994 Aug; 26(2):95-107. PubMed ID: 7994190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.